ImmunoGen, Inc. Announces Webcast of Presentation at the 12th Annual BIO CEO & Investor Conference
WALTHAM, Mass., Feb 02, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 12th Annual BIO CEO & Investor Conference at 2:30 pm ET on February 9, 2010. The Conference is being held at the Waldorf=Astoria hotel in New York City. ImmunoGen's presentation will be webcast live and can be accessed through the "Investor Information" section of our website, www.immunogen.com. An archive of the webcast will be available at the same location until February 14, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's cancer-cell killing agents specifically to tumor targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.
SOURCE: ImmunoGen, Inc.
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
